Covid-Vaccine-Monitor (CVM)

Research question

This study is a Cohort Event Monitoring of safety of COVID-19 vaccines in pregnant and lactating women in Switzerland associated with a large European study.
The primary objective is to generate and compare incidence rates of adverse reactions of different COVID-19 vaccines reported through questionnaires by pregnant and lactating women.
The secondary objective is to identify potential predictors of the most frequently reported adverse reactions related to different COVID-19 vaccines within each special cohort of vaccinees.

Overview

Covid-Vaccine-Monitor (CVM)
Project leader

Project leader in Switzerland: Prof. Alice Panchaud (BIHAM)
Project team

Prof. Alice Panchaud (BIHAM), Prof David Baud (CHUV), Dr Emeline Maisonneuve (BIHAM), Dr Guillaume Favre (CHUV)

Doctoral student(s)

Dr. Emeline Maisonneuve (BIHAM)

Partner(s)

Lead of European project: Pharmacovigilance Center in Lareb and the University Medical Center Utrecht in the Netherlands
Partners: Rotunda Hospital Dublin (Ireland), University of Verona (Italy), CLPP Vaccines Network (Portugal), University of Medicine and Pharmacy ‘Iuliu Hatieganu’ Cluj-Napoca (Romania), SLOVACRIN Pavol Jozef Šafárik University in Košice Faculty of Medicine (Slovakia), Institut Universitari d’Investigació en Atenció Primària Jordi Gol (Spain), Teamit Institute, Barcelona Health Hub (Spain)
 
Study start

December 2021
Funder(s)

European Medicines Agency

Study design

Observational study